Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

Published:2003 Issue:9 Volume:97 Page:2225-2228
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop,Talpaz Moshe,O'Brien Susan,Giles Francis,Beth Rios Mary,White Kevin,Garcia-Manero Guillermo,Ferrajoli Alessandra,Verstovsek Srdan,Wierda William,Kornblau Steven,Cortes Jorge

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Induction of Chronic Myelogenous Leukemia in Mice by the P210 bcr/abl Gene of the Philadelphia Chromosome

2. Chronic Myelogenous Leukemia: Biology and Therapy

3. Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

4. Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials;Frontiers in Oncology;2023-12-20

2. Safety and efficacy of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia: A protocol for systematic review and meta-analysis;Medicine: Case Reports and Study Protocols;2022-03

3. Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib;British Journal of Haematology;2015-11-04

4. Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML);Leukemia Research;2014-08

5. Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia;Clinical Therapeutics;2012-02